News

MONALEESA-3 showed Kisqali plus fulvestrant significantly prolonged progression-free survival (PFS) compared to fulvestrant alone in postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced

The approval is for a 2mg dose of the drug in adult patients who did not show adequate response to one or more tumor necrosis factor (TNF) inhibitor

The interim data from the phase 2 KEYNOTE-427 study showed an ORR of 38.2% in patients who received Keytruda monotherapy as first-line therapy. It is the primary endpoint of

The partnership will assess the safety and efficacy of Nektar's NKTR-214, a CD122-biased agonist, in combination with entinostat, Syndax's oral, small molecule Class 1 specific HDAC inhibitor, in

Researchers want to discover whether AstraZeneca and MSD’s experimental medicine, selumetinib (AZD6244, ARRY-142886), can be effective in combination with dexamethasone, a treatment already used for several conditions including

The double-blind, placebo-controlled phase 2 study included 125 patients over the age of 18 and was undertaken across nearly 25 clinical sites in the US. Patients were randomized

The planned start of the Phase 1b/2 study (68284528MMY2001), scheduled to begin enrollment in the second half of 2018, follows the US Food and Drug Administration (FDA) clearance

The trial did not meet the primary endpoint of a statistically-significant reduction of exacerbations. This news follows the announcement earlier this month that the first pivotal Phase III

The approval is for the drug to be taken orally twice daily (BID) in 10mg dosage for at least eight weeks, followed by 5mg BID or 10mg BID